Lenalidomide and subsequent TP53-mutated myeloid neoplasms, abnormal uterine bleeding after VTE, and novel tri-specific antibody for B-ALL
Blood Podcast
00:00
A Novel CD19 CD22 CD3 Tri-Specific Antibody Enhances Therapeutic Efficacy and Overcomes Immuniscape Against B-a-L-L
Bi-specific antibodies have emerged as a novel treatment option for patients with hemologic and solid malignancies. To date, there have been four bi-specific antibodies approved by the U.S. Food and Drug Administration. One approach to overcoming immune escape is to simultaneously target more than one tumor-associated antigen and cancer cells. Listeners, CME questions for this article are available on the blood website at cme.org.
Transcript
Play full episode
